Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 8
2006 6
2007 9
2008 17
2009 16
2010 28
2011 33
2012 32
2013 37
2014 43
2015 44
2016 32
2017 28
2018 18
2019 18
2020 15
2021 12
2022 12
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

348 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "erlotinib response - Efficacy"
Page 1
Erlotinib.
Steins M, Thomas M, Geißler M. Steins M, et al. Recent Results Cancer Res. 2018;211:1-17. doi: 10.1007/978-3-319-91442-8_1. Recent Results Cancer Res. 2018. PMID: 30069756 Review.
Inhibitors of this pathway have been developed and assessed in trials with significant efficacy in clinical applications. The current review focuses in particular on the clinical data of EGFR tyrosine kinase inhibition in different tumour entities, preferably non-small cel …
Inhibitors of this pathway have been developed and assessed in trials with significant efficacy in clinical applications. The current …
Erlotinib.
Steins M, Thomas M, Geissler M. Steins M, et al. Recent Results Cancer Res. 2014;201:109-23. doi: 10.1007/978-3-642-54490-3_6. Recent Results Cancer Res. 2014. PMID: 24756788 Review.
Inhibitors of this pathway have been developed and assessed in trials with significant efficacy in clinical applications. The current review focuses in particular on the clinical data of EGFR tyrosine kinase inhibition in different tumour entities, preferably non-small cel …
Inhibitors of this pathway have been developed and assessed in trials with significant efficacy in clinical applications. The current …
Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.
Xu Y, Kong W, Cao M, Wang J, Wang Z, Zheng L, Wu X, Cheng R, He W, Yang B, Dong B, Pan J, Chen Y, Huang J, Jiang C, Zhai W, Li F, Chen R, Zhou X, Wu G, Geng X, Chen J, An H, Yuan Y, Xu T, Chen D, Lin D, Xu L, Huang K, Peng L, Yu Y, Tai S, Qi H, Luo K, Kang X, Wang H, Huang Y, Zhang J, Xue W. Xu Y, et al. Eur Urol. 2023 Feb;83(2):163-172. doi: 10.1016/j.eururo.2022.05.029. Epub 2022 Jun 15. Eur Urol. 2023. PMID: 35715365
There is currently limited understanding of the molecular alterations, pathogenesis, survival outcomes, and systemic therapy efficacy for this cancer. OBJECTIVE: To perform a retrospective multicenter analysis of molecular profiling and clinical outcomes for patients with …
There is currently limited understanding of the molecular alterations, pathogenesis, survival outcomes, and systemic therapy efficacy …
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Spira A, Angevin E, Su WC, Hong DS, Strickler JH, Motwani M, Dunbar M, Parikh A, Noon E, Blot V, Wu J, Kelly K. Camidge DR, et al. J Clin Oncol. 2023 Feb 10;41(5):1105-1115. doi: 10.1200/JCO.22.00739. Epub 2022 Oct 26. J Clin Oncol. 2023. PMID: 36288547 Free PMC article. Clinical Trial.
Later enrollment required presence of an EGFR-activating mutation (EGFR-M+) and progression on a prior EGFR TKI. End points included safety, pharmacokinetics, objective response rate (ORR), and progression-free survival (PFS). The efficacy-evaluable population consi …
Later enrollment required presence of an EGFR-activating mutation (EGFR-M+) and progression on a prior EGFR TKI. End points included safety, …
EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study.
Peng P, Gong J, Zhang Y, Zhou S, Li Y, Han G, Meng R, Chen Y, Yang M, Shen Q, Chu Q, Xia S, Zhang P, Zhang L, Chen Y, Zhang L. Peng P, et al. Radiother Oncol. 2023 Jul;184:109681. doi: 10.1016/j.radonc.2023.109681. Epub 2023 Apr 25. Radiother Oncol. 2023. PMID: 37105304 Free article. Clinical Trial.
However, the acquired resistance greatly limits the survival benefit of EGFR-TKIs for EGFR-mutant NSCLC patients. We aimed to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus EGFR-TKIs in these patients. ...Patients who had received first-line E …
However, the acquired resistance greatly limits the survival benefit of EGFR-TKIs for EGFR-mutant NSCLC patients. We aimed to assess the …
Erlotinib.
Steins M, Thomas M, Geissler M. Steins M, et al. Recent Results Cancer Res. 2010;184:21-31. doi: 10.1007/978-3-642-01222-8_2. Recent Results Cancer Res. 2010. PMID: 20072828 Review.
Inhibitors of this pathway have been developed and assessed in trials with significant efficacy in clinical applications. The current review focuses in particular on the clinical data of EGFR tyrosine kinase inhibition in different tumour entities, preferably non-small cel …
Inhibitors of this pathway have been developed and assessed in trials with significant efficacy in clinical applications. The current …
Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
Walia M, Singhal MK, Kamle MS. Walia M, et al. Indian J Cancer. 2022 Mar;59(Supplement):S80-S89. doi: 10.4103/ijc.IJC_50_21. Indian J Cancer. 2022. PMID: 35343193 Free article. Review.
Osimertinib is a third-generation, irreversible, oral EGFR-TKI that potently and selectively inhibits both EGFRm (epidermal growth factor receptor mutated) and EGFR T790M and has demonstrated efficacy in NSCLC central nervous system (CNS) metastases. Trials have reported s …
Osimertinib is a third-generation, irreversible, oral EGFR-TKI that potently and selectively inhibits both EGFRm (epidermal growth factor re …
Pharmacogenetic application in personalized cancer treatment.
Kristyanto H, Utomo AR. Kristyanto H, et al. Acta Med Indones. 2010 Apr;42(2):109-15. Acta Med Indones. 2010. PMID: 20513938 Free article. Review.
Pharmacogenetic is broadly understood as study or clinical testing of genetic variations that contribute to differing response to drugs. In cancer treatment, applications of pharmacogenetic cover three areas: avoidance of adverse drug reaction (ADR), selection of treatment …
Pharmacogenetic is broadly understood as study or clinical testing of genetic variations that contribute to differing response to dru …
Machine learning based personalized drug response prediction for lung cancer patients.
Qureshi R, Basit SA, Shamsi JA, Fan X, Nawaz M, Yan H, Alam T. Qureshi R, et al. Sci Rep. 2022 Nov 7;12(1):18935. doi: 10.1038/s41598-022-23649-0. Sci Rep. 2022. PMID: 36344580 Free PMC article.
In this study, we propose a personalized drug response prediction model (PDRP), based on molecular dynamics simulations and machine learning, to predict the response of first generation FDA-approved small molecule EGFR-TKIs, Gefitinib/Erlotinib, …
In this study, we propose a personalized drug response prediction model (PDRP), based on molecular dynamics simulations and ma …
MEK inhibition in non-small cell lung cancer.
Stinchcombe TE, Johnson GL. Stinchcombe TE, et al. Lung Cancer. 2014 Nov;86(2):121-5. doi: 10.1016/j.lungcan.2014.09.005. Epub 2014 Sep 16. Lung Cancer. 2014. PMID: 25257766 Free PMC article. Review.
A randomized phase II trial of docetaxel with and without selumetinib revealed that the combination resulted numerically superior overall survival, and a statistically significant improvement in progression-free survival and objective response rate. However, a concerning r …
A randomized phase II trial of docetaxel with and without selumetinib revealed that the combination resulted numerically superior overall su …
348 results